Current strategies of allergen-specific immunotherapy



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article discusses the principles of the optimal allergovaccine choice for allergen-specific immunotherapy (ASIT) for grass-pollen-allergy patients; reviewed efficacy and safety studies of the standardized mixt five-grass-pollen extract. Relatively grass sensitization is preferred use mixt grass-pollen extract is thus more suitable for specific immunotherapy, as it contains a broader repertoire of the epitopes, which approximate to the natural exposure conditions.

Full Text

Restricted Access

About the authors

K S Pavlova

Institute of immunology

Email: ksenimedical@gmail.com

O M Kurbacheva

Institute of immunology

References

  1. Курбачева О.М. Клинические, патогенетические и экономические аспекты применения аллерген-специфической иммунотерапии. Диссертация д-ра мед. наук. М., 2007, 198 с.
  2. Карпова Е.П. Лечение аллергического ринита у детей. М., Гэотар-Медиа. 2007, 112с.
  3. Ильина Н.И. Аллергология в различных регионах России по результатам клинико-эпидемиологических исследований. Диссертация д-ра мед. наук. М., 1996, 225 с.
  4. Хаитов Р.М., Богова А.В., Ильина Н.И. Эпидемиология аллергических заболеваний России. Иммунология. 1998, № 3, с. 4-9.
  5. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 Update. Allergy (Suppl. 86). 2008, v. 63, p. 1-160.
  6. Аллергология. Фармакотерапия без ошибок. Руководство для врачей. Под ред. Р.М. Хаитова. М.: «Е-ното». 2013, 496 с.
  7. Bousquet J., Lockey R., Malling H.J. WHO Position Paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy. 1998, v. 53, suppl. No. 44, p. 1-42.
  8. Canonica et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organization Journal. 2014, v. 7, p. 6, http://www.waojournal.org/content/7/1/6.
  9. Eifan A.O., Calderon M.A., Durham S.R. Allergen immunotherapy for house dust mite: clinical efficacy and immunological mechanisms in allergic rhinitis and asthma. Expert Opin. Biol. Ther. 2013, v. 13 (11), p. 1543-1556.
  10. Radulvic S., Calderon M.A., Wilson D., Durham S. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst. Rev. 2010, v. 8 (12), CD002893.
  11. Novembre E., Galli E., Landi F. et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 2004, v. 114, p. 851-857.
  12. Pichler C.E., Marquardsen A., Sparholt S. et al. Specific immunotherapy with Dermatophagoides pteronyssinus and D. farina results in decreased bronchial hyperreactivity. Allergy. 1997, v. 52, p. 274-283.
  13. Zielen S., Kardos P., Madonini E. Steroid-sparing effects with allergen-specific immunotherapy in children with asthma: a randomized controlled trial. J. Allergy Clin. Immunol. 2010, v. 126 (5), p. 942-949.
  14. Akdis M., Schmidt-Weber C., Jutel M. et al. Mechanisms of allergen immunotherapy. Allergy Clin. Immunol. Int. J. World Allergy Org. 2004, v. 16, No. 2, p. 65-69.
  15. Akdis M., Verhagen J., Taylor A. et al. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T-regulatory 1 and T-helper 2 cells. J. Exp. Med. 2004, v. 199, p. 1567-1575.
  16. Francis J.N., Till S.J., Durham S.R. Induction of IL-10+ CD4+CD25+ T-cells by grass pollen immunotherapy. J. Allergy Clin. Immunol. 2003, v. 11, p. 1255-1261.
  17. Ozdemir C. An immunological overview of allergen specific immunotherapy - subcutaneous and sublingual routes. Ther. Adv. Resp. Dis. 2009, v. 3 (5), p. 253-262.
  18. Di Rienzo V., Marcucci F., Pucinelli P. et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin. Exp. Allergy. 2003, v. 33 (2), p. 206-210.
  19. Interactive Agricultural Ecological Atlas of Russia and Neighboring Countries. Available from: http://www.agroatlas.ru/en/content/related/phleum-pratense/map/ [Last accessed 27 June 2015].
  20. Moingeon P., Hrabina M., Bergmann K.C., Jaeger S., Frati F., Bordas V., Peltre G. Specific Immunotherapy for Common Grass Pollen Allergies: Pertinence of a Five Grass Pollen Vaccine. Int. Arch. Allergy Immunol. 2008, v. 146, p. 338-342.
  21. Mari A. Skin test with a timothy grass (Phleum pratense) pollen extract vs IgE to a timothy extract vs IgE to rPhl p 1, rPhl p 2, nPhl p 4, rPhl p 5, rPhl p 6, rPhl p 7, rPhl p 11, and rPhl p 12: epidemiological and diagnostic data. Clin. Exp. Allergy. 2003, v. 33, p. 43-51.
  22. Chabre H., Gouyon B., Huet A. et al. Molecular variability of group 1 and 5 grass pollen allergens between Pooideae species: implications for immunotherapy. Clin. Exp. Allergy. 2010, v. 40 (3), p. 505-519.
  23. Andersson K., Lidholm J. Characteristics and immunobiology of grass pollen allergens. Int. Arch. Allergy Immunol. 2003, v. 130, p. 87-107.
  24. Ferreira F., Hawranek T., Gruber P., Wopfner N., Mari A. Allergic cross-reactivity: from gene to the clinic. Allergy. 2004, v. 59, p. 243-267.
  25. Weber R.W. Cross-reactivity ofpollen allergens: recommendations for immunotherapy vaccines. Curr. Opin. Allergy Clin. Immunol. 2005, v. 5, p. 563-569.
  26. Levin M., Rotthus S., Wendel S., Najafi N., Kallstrom E., Focke-Tejkl M., Valenta R., Flicker S., Ohlin M. Multiple independent IgE epitopes on the highly allergenic grass pollen allergen Phl p 5. Clin. Exp. Allergy. 2014, v. 44, p. 1409-1419.
  27. Bullimore A., Swan N., Alawode W., Skinner M. A proteomic style approach to characterize a grass mix product reveals potential immunotherapeutic benefit. WAO Journal. 2011, v. 4, p. 140-146.
  28. Didier A., Wahn U., Horak F., Cox L. Five-grass-pollen sublingual immunotherapy tablet for the treatment of grass-pollen-induced allergic rhinoconjunctivitis - 5 years of experience. Expert Rev. Clin. Immunol. Early online. 2014, p. 1-16.
  29. Didier A., Malling H.J., Worm M., Horak F., Jäger S., Montagut A., Andre C., de Beaumont O., Melac M. Optimal dose, efficacy and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J. Allergy Clin. Immunol. 2007, v. 120, p. 1338-1345.
  30. Durham S., Varney V., Gaga M. Grass pollens immunotherapy remains effective 3 years after discontinuation: a double-blind, placebo-controlled withdrawal study. Clin. Exp. Allergy. 1998, v. 88, p. 43-53.
  31. Ortolani C., Pastorello E., Moss R.B. Grass pollen immunotherapy: a single year double-blind, placebo-controlled study in patients with grass pollen-induced asthma and rhinitis. J. Allergy Clin. Immunol. 1984, v. 73, p. 283-290.
  32. Calderon M.A., Larenas D., Kleine-Tebbe J. et al. European academy of allergy and clinical immunology task force report on ‘dose-response relationship in allergen-specific immunotherapy’. Allergy. 2011, v. 66, p. 1345-1359.
  33. Chapman M.D., Ferreira F., Villalba M. et al. The European Union CREATE project: a model for international standardization of allergy diagnostics and vaccines. J. Allergy Clin. Immunol. 2008, v. 122, p. 882-889.
  34. Larenas-Linnemann D., Esch R., Plunkett G. et al. Maintenance dosing for sublingual immunotherapy by prominent European allergen manufacturers expressed in bioequivalent allergy units. Ann. Allergy Asthma Immunol. 2011, v. 107, p. 448-458.
  35. Van Ree R., Chapman M.D., Ferreira F. et al. The CREATE project: development of certified reference materials for allergenic products and validation of methods for their quantification. Allergy. 2008, v. 63, p. 310-326.
  36. Durham S.R., Yang W.H., Pedersen M.R., Johansen N., Ral S. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 2006, v. 117, p. 802-809.
  37. Prescribing information for ORALAIR in the US. Available from http://dailymed.nlm.nih.gov/daylimed/fda/fdaDrugXsl.cfm?setid=854c9772-63b9-44a3-a11e77b29c59e91d&-type=display [Last accent 22 January 2015].
  38. FDA Briefing Document Biological License Application (BLA) for Timothy Grass Pollen Allergen Extract Tablet for Sublingual Use. Available from http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/bloodvaccineasandotherbiologics/allergenicproductsadvisorycommittee/ucm378092.pdf [Last accessed 27 June 2015].
  39. Canonica G.W., Baena-Cagnani C.E., Bousquet J. et al. Recommendations for the standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy. 2007, v. 62 (3), p. 317-324.
  40. Juniper E.F., Thompson A.K., Roberts J.N. Can the standard gamble and rating scale be used to measure quality of life in rinoconjunctivitis? Comparison with the RQLQ and SF-36. Allergy. 2002, v. 57, p. 201-206.
  41. Barley E.A., Quirk F.H., Jones P.W. Asthma health status measurement in clinic practice. Validity of a new short and simple instrument. Respiratory Medicine. 1998, v. 92, p. 1207-1214.
  42. Whan U., Tabar A., Kuna P. et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 2009, v. 123, p. 160-166.
  43. Horak F., Zieglmayer P., Zieglmayer R. et al. Early onset of action of a 5-grass-pollen-300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber. J. Allergy Clin. Immunol. 2009, v. 124, p. 471-477.
  44. Didier A., Worm M., Horak F. et al. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis. J. Allergy Clin. Immunol. 2011, v. 128, p. 559-566.
  45. Karagianis E., Hadler M., Shan-Hosseini K. et al. Non-interventional 2-year study of sublingual immunotherapy in patients with allergic rhinoconjunctivitis caused by grass pollen. Presented at European Academy of Allergy and Clinical Immunology (EAACI). Annual Meeting. Milan, Italy. 2013.
  46. Oralair® Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass Mixed Pollens Allergen Extract Tablet for Sublingual Use: Food and Drug Administration Allergenic Products Advisory Committee Briefing Document. Stallergenes S.A., 2013. Available from: http://www.fda.gov/downloads/advisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/AllergenicProducts-AdvisoryCommittee/UCM377851.pdf [Last accessed 27 June 2015].

Copyright © Pharmarus Print Media, 2015



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies